Founded at MIT, Kano is bridging the gap between editing genes and totally replacing them, unlocking the broad use of single-stranded DNA payloads for cell and gene therapies. The company is developing and collaborating on therapies that safely, effectively and flexibly correct gene-length stretches of DNA inaccessible to today's editing techniques.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/12/24 | $7,100,000 | Seed |
MetaPlanet Holdings Taihill Venture The Engine  Vsquared Ventures | undisclosed |
